Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents

Ian R. Corbin, Hui Li, Juan Chen, Sissel Lund-Katzy, Rong Zhou, Jerry D. Glickson, Gang Zheng

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Low-density lipoproteins (LDLs) are a naturally occurring endogenous nanoplatform in mammalian systems. These nanoparticles (22 nm) specifically transport cholesterol to cells expressing the LDL receptor (LDLR). Several tumors overexpress LDLRs presumably to provide cholesterol to sustain a high rate of membrane synthesis. Amphiphilic gadolinium (Gd)-diethylenetriamine pentaacetic acid chelates have been incorporated into the LDL to produce a novel LDLR-targeted magnetic resonance imaging (MRI) contrast agent. The number of Gd chelates per LDL particle ranged between 150 and 496 Gd(III). In vitro studies demonstrated that Gdlabeled LDL retained a similar diameter and surface charge as the native LDL particle. In addition, Gd-labeled LDL retained selective cellular binding and uptake through LDLR-mediated endocytosis. Finally, Gd-labeled LDLs exhibited significant contrast enhancement 24 hours after administration in nude mice with human hepatoblastoma G2 xenografts. Thus, Gd-labeled LDL demonstrates potential use as a targeted MRI contrast agent for in vivo tumor detection.

Original languageEnglish (US)
Pages (from-to)488-498
Number of pages11
JournalNeoplasia
Volume8
Issue number6
DOIs
StatePublished - 2006

Fingerprint

LDL Lipoproteins
Nanoparticles
Contrast Media
Gadolinium
Magnetic Resonance Imaging
LDL Receptors
Cholesterol
Hepatoblastoma
Pentetic Acid
Endocytosis
Heterografts
Nude Mice
Neoplasms
Membranes

Keywords

  • Human hepatoblastoma G (HepG)
  • Low-density lipoprotein (LDL)
  • Low-density lipoprotein receptor
  • Magnetic resonance imaging (MRI)
  • Nanoparticle

ASJC Scopus subject areas

  • Cancer Research

Cite this

Corbin, I. R., Li, H., Chen, J., Lund-Katzy, S., Zhou, R., Glickson, J. D., & Zheng, G. (2006). Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia, 8(6), 488-498. https://doi.org/10.1593/neo.05835

Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. / Corbin, Ian R.; Li, Hui; Chen, Juan; Lund-Katzy, Sissel; Zhou, Rong; Glickson, Jerry D.; Zheng, Gang.

In: Neoplasia, Vol. 8, No. 6, 2006, p. 488-498.

Research output: Contribution to journalArticle

Corbin, IR, Li, H, Chen, J, Lund-Katzy, S, Zhou, R, Glickson, JD & Zheng, G 2006, 'Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents', Neoplasia, vol. 8, no. 6, pp. 488-498. https://doi.org/10.1593/neo.05835
Corbin, Ian R. ; Li, Hui ; Chen, Juan ; Lund-Katzy, Sissel ; Zhou, Rong ; Glickson, Jerry D. ; Zheng, Gang. / Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. In: Neoplasia. 2006 ; Vol. 8, No. 6. pp. 488-498.
@article{b4d85e124cd1435aa9f589809b70ad09,
title = "Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents",
abstract = "Low-density lipoproteins (LDLs) are a naturally occurring endogenous nanoplatform in mammalian systems. These nanoparticles (22 nm) specifically transport cholesterol to cells expressing the LDL receptor (LDLR). Several tumors overexpress LDLRs presumably to provide cholesterol to sustain a high rate of membrane synthesis. Amphiphilic gadolinium (Gd)-diethylenetriamine pentaacetic acid chelates have been incorporated into the LDL to produce a novel LDLR-targeted magnetic resonance imaging (MRI) contrast agent. The number of Gd chelates per LDL particle ranged between 150 and 496 Gd(III). In vitro studies demonstrated that Gdlabeled LDL retained a similar diameter and surface charge as the native LDL particle. In addition, Gd-labeled LDL retained selective cellular binding and uptake through LDLR-mediated endocytosis. Finally, Gd-labeled LDLs exhibited significant contrast enhancement 24 hours after administration in nude mice with human hepatoblastoma G2 xenografts. Thus, Gd-labeled LDL demonstrates potential use as a targeted MRI contrast agent for in vivo tumor detection.",
keywords = "Human hepatoblastoma G (HepG), Low-density lipoprotein (LDL), Low-density lipoprotein receptor, Magnetic resonance imaging (MRI), Nanoparticle",
author = "Corbin, {Ian R.} and Hui Li and Juan Chen and Sissel Lund-Katzy and Rong Zhou and Glickson, {Jerry D.} and Gang Zheng",
year = "2006",
doi = "10.1593/neo.05835",
language = "English (US)",
volume = "8",
pages = "488--498",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents

AU - Corbin, Ian R.

AU - Li, Hui

AU - Chen, Juan

AU - Lund-Katzy, Sissel

AU - Zhou, Rong

AU - Glickson, Jerry D.

AU - Zheng, Gang

PY - 2006

Y1 - 2006

N2 - Low-density lipoproteins (LDLs) are a naturally occurring endogenous nanoplatform in mammalian systems. These nanoparticles (22 nm) specifically transport cholesterol to cells expressing the LDL receptor (LDLR). Several tumors overexpress LDLRs presumably to provide cholesterol to sustain a high rate of membrane synthesis. Amphiphilic gadolinium (Gd)-diethylenetriamine pentaacetic acid chelates have been incorporated into the LDL to produce a novel LDLR-targeted magnetic resonance imaging (MRI) contrast agent. The number of Gd chelates per LDL particle ranged between 150 and 496 Gd(III). In vitro studies demonstrated that Gdlabeled LDL retained a similar diameter and surface charge as the native LDL particle. In addition, Gd-labeled LDL retained selective cellular binding and uptake through LDLR-mediated endocytosis. Finally, Gd-labeled LDLs exhibited significant contrast enhancement 24 hours after administration in nude mice with human hepatoblastoma G2 xenografts. Thus, Gd-labeled LDL demonstrates potential use as a targeted MRI contrast agent for in vivo tumor detection.

AB - Low-density lipoproteins (LDLs) are a naturally occurring endogenous nanoplatform in mammalian systems. These nanoparticles (22 nm) specifically transport cholesterol to cells expressing the LDL receptor (LDLR). Several tumors overexpress LDLRs presumably to provide cholesterol to sustain a high rate of membrane synthesis. Amphiphilic gadolinium (Gd)-diethylenetriamine pentaacetic acid chelates have been incorporated into the LDL to produce a novel LDLR-targeted magnetic resonance imaging (MRI) contrast agent. The number of Gd chelates per LDL particle ranged between 150 and 496 Gd(III). In vitro studies demonstrated that Gdlabeled LDL retained a similar diameter and surface charge as the native LDL particle. In addition, Gd-labeled LDL retained selective cellular binding and uptake through LDLR-mediated endocytosis. Finally, Gd-labeled LDLs exhibited significant contrast enhancement 24 hours after administration in nude mice with human hepatoblastoma G2 xenografts. Thus, Gd-labeled LDL demonstrates potential use as a targeted MRI contrast agent for in vivo tumor detection.

KW - Human hepatoblastoma G (HepG)

KW - Low-density lipoprotein (LDL)

KW - Low-density lipoprotein receptor

KW - Magnetic resonance imaging (MRI)

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=33745832274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745832274&partnerID=8YFLogxK

U2 - 10.1593/neo.05835

DO - 10.1593/neo.05835

M3 - Article

VL - 8

SP - 488

EP - 498

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 6

ER -